We uphold rigorous standards through EU-GMP certification, independent testing, and continuous technological evaluations. Our team's strong pharmaceutical and medicinal cannabis expertise ensures the highest safety and quality levels.

We currently hold scientific-use cannabis handling approvals and we are pursuing further licenses, including wholesaler license for APO and medicinal products, CanG license for cannabis processing and last but not least the EU-GMP certification, to meet stringent standards.

Yes, by eliminating microbial threats without harming the plant, cold plasma extends shelf life while maintaining potency and safety.

GOC Nexus’s cold plasma sterilization is a unique, non-invasive method that decontaminates cannabis without compromising its quality. Unlike traditional methods such as irradiation—which can alter the chemovar profile—our patented process preserves the product’s natural taste, aroma, and efficacy.

Independent tests confirm our process preserves cannabinoids, terpenes, taste, and aroma—unlike other methods that often degrade product quality.

Cold plasma operates at near-room temperatures using safe, reactive species that deactivate microbes while preserving THC, terpenes, and other key compounds.

Cold plasma is ionised gas at low temperatures used for sterilisation in pharma and food industries—proving its safety and effectiveness in multiple sectors.

Do you know that Canada has destroyed in the last three years more than 1,500 tons of unpacked dried cannabis flowers? The cannabis industry increasingly demands non-destructive decontamination. Our cold plasma technology effectively eliminates contaminants while preserving the plant’s natural profile—ideal for cultivators, wholesalers, and producers.

We serve B2B clients in both medical (Europe) and recreational sectors (North America). Our main customers include cannabis cultivators, raw material wholesalers, and producers searching for safe and efficient decontamination solutions.

With nearly 90% of production capacity already pre-sold, we’re scaling by launching 25 service centres in the non-GMP field and 4-6 centres for EU-GMP in the key regulated markets over the next years. Strategic partnerships and signed LOIs ensure stable monthly demand.

Market entry for the Canadian domestic market started in 2024. For Germany, the EU-GMP rollout of the pharmaceutical manufacturing service is planned for the end of 2025—aligned with regulatory strategies and industry demand.

Our system can process with one machine 12 tons annually under a 3-shift operation, with potential for significant expansion as market demand rises.

Our operational launch for the German pilot EU-GMP facility is funded through a €1.4 million bank loan and a €600k strategic investment. With over 90% of capacity booked for three-shift operations, we are poised for rapid expansion.

While regulatory risks exist as in any emerging market, our patented technology and growing demand mitigate these. This positions us as a high-growth opportunity in cannabis decontamination.

Our process is more energy-efficient and gentler on the product than irradiation. This translates to better quality and long-term cost savings.

Our leadership team includes seasoned experts from the cannabis and pharmaceutical industries, with proven success in scaling operations and achieving EU-GMP certification.

We’ve completed technology assessments, market testing, and secured binding contracts. Our facilities, scalable machines, and successful independent tests ensure we’re launch-ready.